MX2021000289A - Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. - Google Patents
Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.Info
- Publication number
- MX2021000289A MX2021000289A MX2021000289A MX2021000289A MX2021000289A MX 2021000289 A MX2021000289 A MX 2021000289A MX 2021000289 A MX2021000289 A MX 2021000289A MX 2021000289 A MX2021000289 A MX 2021000289A MX 2021000289 A MX2021000289 A MX 2021000289A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- hypercholesterolemia
- cardiovascular risk
- high cardiovascular
- present
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 208000035150 Hypercholesterolemia Diseases 0.000 title abstract 3
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 3
- 229940122392 PCSK9 inhibitor Drugs 0.000 abstract 2
- 208000029078 coronary artery disease Diseases 0.000 abstract 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 231100000682 maximum tolerated dose Toxicity 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención proporciona métodos para tratar la hipercolesterolemia. Los métodos de la presente invención comprenden administrar a un paciente de alto riesgo cardiovascular una composición farmacéutica que comprende un inhibidor de PCSK9. En determinadas modalidades, el inhibidor de PCSK9 es un anticuerpo anti-PCSK9, tal como el anticuerpo ilustrativo referido en la presente descripción como mAb316P. Los métodos de la presente invención son útiles para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia y cardiopatía coronaria (CC) establecida o equivalentes de riesgo de CC no adecuadamente controladas con terapia de estatinas a la dosis máxima tolerada.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462025371P | 2014-07-16 | 2014-07-16 | |
| US201462043167P | 2014-08-28 | 2014-08-28 | |
| US201462080725P | 2014-11-17 | 2014-11-17 | |
| US201562132709P | 2015-03-13 | 2015-03-13 | |
| EP15305830 | 2015-05-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000289A true MX2021000289A (es) | 2021-03-31 |
Family
ID=53365943
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000628A MX2017000628A (es) | 2014-07-16 | 2015-07-16 | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. |
| MX2021000289A MX2021000289A (es) | 2014-07-16 | 2017-01-13 | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017000628A MX2017000628A (es) | 2014-07-16 | 2015-07-16 | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20160137746A1 (es) |
| EP (2) | EP3169362B1 (es) |
| JP (1) | JP6912374B2 (es) |
| KR (3) | KR20240132123A (es) |
| CN (2) | CN107106678A (es) |
| AU (1) | AU2015289617B2 (es) |
| CA (1) | CA2955304C (es) |
| MX (2) | MX2017000628A (es) |
| PL (1) | PL3169362T3 (es) |
| RU (1) | RU2723018C2 (es) |
| WO (1) | WO2016011260A1 (es) |
| ZA (1) | ZA201700196B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
| US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
| CA2914721A1 (en) | 2013-06-07 | 2014-12-11 | Regeneron Pharmaceuticals, Inc. | Methods for inhibiting atherosclerosis by administering an inhibitor of pcsk9 |
| TWI670077B (zh) | 2013-11-12 | 2019-09-01 | 賽諾菲生物技術公司 | 使用ｐｃｓｋ９抑制劑之給藥療程 |
| KR20240017117A (ko) | 2014-07-16 | 2024-02-06 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| WO2016046684A1 (en) * | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
| KR20240172758A (ko) | 2015-08-18 | 2024-12-10 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
| TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法 |
| RU2020132463A (ru) * | 2018-03-06 | 2022-04-06 | Санофи Байотекнолоджи | Применение ингибитора pcsk9 для снижения сердечно-сосудистого риска |
| WO2021098720A1 (zh) * | 2019-11-18 | 2021-05-27 | 康融东方（广东）医药有限公司 | 抗pcsk9抗体及其应用 |
| WO2022032137A1 (en) * | 2020-08-07 | 2022-02-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BR112013018740A2 (pt) * | 2011-01-28 | 2019-01-08 | Sanofi Sa | anticorpos humanos para pcsk9 para uso em métodos de tratamento de grupos específicos de indivíduos |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| US20130006482A1 (en) * | 2011-06-30 | 2013-01-03 | Ramadev Burigsay Hukkeri | Guidance system for a mobile machine |
| AU2012308797B2 (en) * | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
| EP2706070A1 (en) * | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
| HUE066839T2 (hu) * | 2014-03-17 | 2024-09-28 | Sanofi Biotechnology | Eljárások kardiovaszkuláris kockázat csökkentésére |
-
2015
- 2015-07-16 JP JP2017502259A patent/JP6912374B2/ja active Active
- 2015-07-16 CA CA2955304A patent/CA2955304C/en active Active
- 2015-07-16 PL PL15760317T patent/PL3169362T3/pl unknown
- 2015-07-16 EP EP15760317.6A patent/EP3169362B1/en active Active
- 2015-07-16 WO PCT/US2015/040765 patent/WO2016011260A1/en active Application Filing
- 2015-07-16 MX MX2017000628A patent/MX2017000628A/es unknown
- 2015-07-16 CN CN201580049703.6A patent/CN107106678A/zh active Pending
- 2015-07-16 KR KR1020247028498A patent/KR20240132123A/ko not_active Application Discontinuation
- 2015-07-16 EP EP20174278.0A patent/EP3753575A1/en not_active Withdrawn
- 2015-07-16 RU RU2017104799A patent/RU2723018C2/ru active
- 2015-07-16 AU AU2015289617A patent/AU2015289617B2/en active Active
- 2015-07-16 US US14/801,392 patent/US20160137746A1/en not_active Abandoned
- 2015-07-16 KR KR1020177004219A patent/KR102482375B1/ko not_active Application Discontinuation
- 2015-07-16 KR KR1020227045465A patent/KR20230007538A/ko not_active Application Discontinuation
- 2015-07-16 CN CN202111397525.XA patent/CN114306592A/zh active Pending
-
2017
- 2017-01-10 ZA ZA2017/00196A patent/ZA201700196B/en unknown
- 2017-01-13 MX MX2021000289A patent/MX2021000289A/es unknown
-
2019
- 2019-10-24 US US16/662,313 patent/US20200255544A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3169362A1 (en) | 2017-05-24 |
| EP3753575A1 (en) | 2020-12-23 |
| RU2017104799A (ru) | 2018-08-16 |
| CN114306592A (zh) | 2022-04-12 |
| RU2017104799A3 (es) | 2019-02-19 |
| PL3169362T3 (pl) | 2020-12-28 |
| RU2723018C2 (ru) | 2020-06-08 |
| CA2955304C (en) | 2023-12-12 |
| US20160137746A1 (en) | 2016-05-19 |
| EP3169362B1 (en) | 2020-06-10 |
| KR20230007538A (ko) | 2023-01-12 |
| CA2955304A1 (en) | 2016-01-21 |
| CN107106678A (zh) | 2017-08-29 |
| ZA201700196B (en) | 2024-09-25 |
| US20200255544A1 (en) | 2020-08-13 |
| AU2015289617A1 (en) | 2017-02-02 |
| KR20170028441A (ko) | 2017-03-13 |
| KR20240132123A (ko) | 2024-09-02 |
| MX2017000628A (es) | 2017-04-27 |
| JP6912374B2 (ja) | 2021-08-04 |
| AU2015289617B2 (en) | 2021-04-15 |
| WO2016011260A1 (en) | 2016-01-21 |
| JP2017522316A (ja) | 2017-08-10 |
| KR102482375B1 (ko) | 2022-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000289A (es) | Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia. | |
| MX2016010504A (es) | Metodos para el tratamiento de pacientes con hipercolesterolemia que no esta controlada adecuadamente por una terapia con estatinas de dosis moderada referencia cruzada a solicitudes relacionas. | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| MX2022013172A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| PH12018500097A1 (en) | Combination of pd-1 antagonist with an egfr inhibitor | |
| MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
| EA201590457A1 (ru) | Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| BR112015026021A2 (pt) | terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| TW201613578A (en) | Pharmaceutical combinations | |
| MX2018002000A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
| WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
| EA201991175A1 (ru) | Применение в медицине интерферона-лямбда для лечения фиброза | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| WO2018052891A3 (en) | MODULATION OF PCSK9 AND LDLR BY INHIBITION OF DRP1 | |
| MY186840A (en) | Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| MX2018011607A (es) | Sultiame para el tratamiento de apnea del sueño. | |
| UA87715U (uk) | Спосіб лікування хворих початковою або розвиненою непроліферативною діабетичною ретинопатією | |
| UA104030U (uk) | Спосіб лікування хворих із загостренням хронічного бронхіту вірусної етіології | |
| UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності |